2321: Clinical Trial of Procaspase-3 Activator (PAC-1) in Combination with Hydroxyurea for Treatment of Canine Meningioma
Grant Status: Open
AbstractPrimary brain tumors are a significant cause of illness and death in pet dogs, with meningioma accounting for approximately half of the cases seen by veterinary neurologists and oncologists. Although surgery remains the best treatment for dogs with meningioma, some dogs are not good candidates for this approach based on their tumor size and/or location. Dogs also may experience tumor regrowth after an attempt is made to surgically remove the tumor. In these situations, effective treatment options are limited. Thus, new investigations are needed to develop new treatments that are both safe and effective for dogs with meningioma.
In order to address this unmet need for dogs with meningioma, we propose a pilot clinical study with the primary goal of determining safety and effectiveness of a new chemotherapy approach. A unique team of investigators from the National Cancer Institute's Comparative Oncology Program (NCI-COP) and selected veterinary academic centers will work together to provide access to state-of-the art imaging and a novel therapeutic approach for dogs with meningioma that are good surgical candidates. Dogs enrolled in this study will receive an investigational combination of chemotherapy agents (PAC-1 + hydroxyurea) and will be monitored with state-of-the-art magnetic resonance and non-invasive molecular imaging techniques. Dogs will then undergo tumor removal so that changes in the tumor can be correlated back to results of imaging studies. This approach is the first to validate and advance a new therapy that is directly applicable to dogs, and potentially also to humans, with advanced, locally-recurrent, and/or non-resectable meningioma.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.